趋化因子配体19在系统性红斑狼疮中的表达及其与B细胞异常的相关性研究

doi:10.3969/j.issn.1671-167X.2017.05.015

摘要/Abstract

摘要： 目的检测趋化因子配体19(C-C chemokine ligand 19, CCL19)在系统性红斑狼疮(systemic lupus erythematosus, SLE)患者血清中的表达,并分析其与SLE患者临床和实验室指标的关系,探讨CCL19在SLE发病机制中的可能作用。方法采用酶联免疫吸附试验(enzyme linked immunosorbent assay, ELISA)法检测90例SLE患者(未接受过糖皮质激素和免疫抑制剂治疗的初治患者15例,曾治疗过的患者75例)和30名健康对照血清中CCL19的表达水平,分析SLE患者血清CCL19水平与临床特征和实验室指标的相关性。利用流式细胞术检测SLE患者B细胞及其亚群的比例,并进行血清CCL19水平与B细胞及其亚群比例的相关性分析。数据分析采用独立样本t检验、配对t检验、Pearson和Spearman相关分析。结果 (1)SLE初治患者和经治患者血清CCL19表达水平[分别为(596.25±409.19) ng/L和(422.90±395.84) ng/L]显著高于健康对照组[(157.79±125.23) ng/L,P均<0.001],初治患者组血清CCL19表达水平又高于经治患者组(P<0.05);(2)SLE患者血清CCL19表达水平与抗双链脱氧核糖核酸(double-stranded deoxyribonucleic acid, dsDNA)抗体、抗核小体抗体(anti-nucleosome antibody, AnuA)水平呈正相关(分别为r=0.38, P=0.007; r=0.332, P=0.029),与免疫球蛋白IgA、IgG、IgM水平呈正相关(分别为r=0.30, P=0.005; r=0.31, P=0.003; r=0.469, P=0.0001);(3)SLE有光过敏、关节炎和继发干燥综合征患者血清CCL19表达水平[分别为(562.25±399.12) ng/L、(565.6±435.24) ng/L和(694.9±531.02) ng/L]分别较无光过敏、无关节炎和未继发干燥综合征SLE患者高[分别为(394.7±281.42) ng/L、(385.90±325.33) ng/L和(424.8±305.46) ng/L],P均<0.05;(4)血清CCL19水平与外周血CD27^-B 细胞和CD27^-IgD^-双阴性记忆性 B 细胞的比例呈正相关(分别为r=0.519, P=0.007; r=0.461, P=0.018),与CD27⁺记忆性B细胞和CD27⁺IgD^-转化后记忆性B细胞的比例呈负相关(分别为r=-0.433, P=0.027; r=-0.616, P=0.001)。结论 SLE患者血清中高表达CCL19,与自身抗体的产生显著相关,CCL19可能通过影响B细胞亚群分布的内稳态参与SLE发病。

关键词: 红斑狼疮, 系统性, 趋化因子配体19, B细胞, 自身抗体

Abstract: Objective: To detect the levels of serum C-C chemokine ligand 19 (CCL19) in patients with systemic lupus erythematosus (SLE) and to evaluate the correlation between CCL19 expression and clinical features and laboratory parameters, trying to reveal the possible role of CCL19 in the pathogenesis of systemic lupus erythematosus. Methods: The levels of serum CCL19 were measured by enzyme linked immunosorbent assay (ELISA) in 90 patients with SLE and 30 healthy controls. These SLE patients included 75 patients who received treatment with glucocorticoids and disease-modifying anti-rheumatic drug (DMARD) and 15 patients without therapy. The frequencies of peripheral blood B cells and the B cell subsets were assessed in the patients with SLE by flow cytometry. The correlation between the clinical data, laboratory parameters, B cell subset frequencies and serum CCL19 levels were analyzed. Indepen-dent samples t test, paired t test, Pearson and Spearman correlation were used for statistical analyses. Results: The levels of CCL19 were markedly higher in the SLE patients without therapy and the patients with therapy than in the health controls[(596.25±409.19) ng/L and (422.90±395.84) ng/L vs. (157.79±125.23) ng/L, all P<0.001]. Serum CCL19 levels in the SLE patients without therapy were higher than the SLE patients who accepted glucocorticoids and DMARD treatment (P<0.05). The levels of serum CCL19 were positively correlated with anti-double stranded deoxyribonucleic acid (dsDNA), anti-nucleosome antibody (AnuA), IgA, IgG and IgM (r=0.38, P=0.007; r=0.332, P=0.029; r=0.519, P=0.007; r=0.461, P=0.018, respectively). Serum CCL19 levels in the SLE patients with photosensitivity, arthritis and secondary Sjögren’s syndrome were higher than the SLE patients without photosensitivity, arthritis and secondary Sjögren’s syndrome, respectively [(562.25±399.12) ng/L, (565.6±435.24) ng/L and (694.9±531.02) ng/L vs. (394.7±281.42) ng/L, (385.90±325.33) ng/L and (424.8±305.46) ng/L, all P<0.05]. The levels of serum CCL19 were positively correlated with the percentage of CD27-B cells and CD27-IgD-double-negative memory B cells (r=0.519, P=0.007; r=0.461, P=0.018, respectively). However, the levels of serum CCL19 were negatively correlated with the percentage of CD27⁺ memory B cells and CD27⁺IgD^- switched memory B cells (r=-0.433, P=0.027; r=-0.616, P=0.001, respectively). Conclusion: The increased serum CCL19 levels in SLE patients were associated with the production of autoantibodies, and CCL19 might be involved in the pathogenesis of SLE by disturbing the homeostasis of B cell subsets.

Key words: Lupus erythematosus, systemic, C-C chemokine ligand 19, B cell, Autoantibody

中图分类号:

R593.24

刘洪江, 石连杰, 胡凡磊, 姚海红, 栗占国, 贾园. 趋化因子配体19在系统性红斑狼疮中的表达及其与B细胞异常的相关性研究[J]. 北京大学学报(医学版), 2017, 49(5): 829-834.

LIU Hong-jiang, SHI Lian-jie, HU Fan-lei, YAO Hai-hong, LI Zhan-guo, JIAYuan. Increased serum C-C chemokine ligand 19 levels correlated with B cell abnormalities in systemic lupus erythematosus[J]. Journal of Peking University(Health Sciences), 2017, 49(5): 829-834.

参考文献

[1] Wahren-Herlenius M, Dorner T. Immunopathogenic mechanisms of systemic autoimmune disease[J]. Lancet, 2013, 382(9894):819-831.
[2] Dorner T, Giesecke C, Lipsky PE. Mechanisms of B cell autoimmunity in SLE[J]. Arthritis Res Ther, 2011, 13(5): 243.
[3] Sanz I. Rationale for B cell targeting in SLE[J]. Semin Immunopathol, 2014, 36(3): 365-375.
[4] Le Y, Zhou Y, Iribarren P, et al. Chemokines and chemokine receptors: their manifold roles in homeostasis and disease[J]. Cell Mol Immunol, 2004, 1(2): 95-104.
[5] Bachmann MF, Kopf M, Marsland BJ. Chemokines: more than just road signs[J]. Nat Rev Immunol, 2006, 6(2): 159-164.
[6] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1997, 40(9): 1725.
[7] Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000[J]. J Rheumatol, 2002, 29(2): 288-291.
[8] Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity[J]. Nat Immunol, 2001, 2(9): 764-766.
[9] Jacob N, Stohl W. Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future[J]. Autoimmunity, 2010, 43(1): 84-97.
[10] Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus[J]. J Immunol, 2000, 165(10): 5970-5979.
[11] Rodriguez-Bayona B, Ramos-Amaya A, Perez-Venegas JJ, et al. Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients[J]. Arthritis Res Ther, 2010, 12(3): R108.
[12] Korganow AS, Knapp AM, Nehme-Schuster H, et al. Peripheral B cell abnormalities in patients with systemic lupus erythematosus in quiescent phase: decreased memory B cells and membrane CD19 expression[J]. J Autoimmun, 2010, 34(4): 426-434.
[13] Blair PA, Norena LY, Flores-Borja F, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients[J]. Immunity, 2010, 32(1): 129-140.
[14] Jin L, Weiqian C, Lihuan Y. Peripheral CD24hi CD27 + CD19 + B cells subset as a potential biomarker in naive systemic lupus erythematosus[J]. Int J Rheum Dis, 2013, 16(6): 698-708.
[15] Yu SL, Kuan WP, Wong CK, et al. Immunopathological roles of cytokines, chemokines, signaling molecules, and pattern-recognition receptors in systemic lupus erythematosus[J]. Clin Dev Immunol, 2012, 2012: 715190.
[16] Okamoto H, Kobayashi A, Yamanaka H. Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus[J]. J Biomed Biotechnol, 2010, 2010: 268436.
[17] 吴春晨, 何玉玲, 陈朗, 等. CXCL13和CCL19联合诱导的B淋巴细胞白血病细胞抗凋亡作用[J]. 医学研究通讯, 2004, 33(12): 12-14.
[18] Sellam J, Rouanet S, Hendel-Chavez H, et al. CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis[J]. Arthritis Rheum, 2013, 65(9): 2253-2261.
[19] Mathes AL, Christmann RB, Stifano G, et al. Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin[J]. Ann Rheum Dis, 2014, 73(10): 1864-1872.
[20] Fecteau JF, Cote G, Neron S. A new memory CD27 - IgG + B cell population in peripheral blood expressing VH genes with low frequency of somatic mutation[J]. J Immunol, 2006, 177(6): 3728-3736.
[21] Wei C, Anolik J, Cappione A, et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus[J]. J Immunol, 2007, 178(10): 6624-6633.
[22] Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig)M + IgD + peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells[J]. J Exp Med, 1998, 188(9): 1679-1689.
[23] Jacobi AM, Reiter K, Mackay M, et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95[J]. Arthritis Rheum, 2008, 58(6): 1762-1773.
[24] Nanki T, Takada K, Komano Y, et al. Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis[J]. Arthritis Res Ther, 2009, 11(5): R149.

相关文章 15

[1]	马豆豆, 马晓彩, 常天静, 王丽芳, 丁艳, 石连杰. 临床表现似系统性红斑狼疮的大B细胞淋巴瘤骨髓受累1例[J]. 北京大学学报（医学版）, 2026, 58(3): 666-669.
[2]	汤晓菲, 丁秋玲, 张阳, 王育梅, 田美伊, 孙卓, 王荣荣, 陈妍, 刘坚. 阿伐曲泊帕治疗难治性系统性红斑狼疮相关血小板减少1例[J]. 北京大学学报（医学版）, 2026, 58(2): 405-409.
[3]	李欣艺, 赵金霞, 穆荣. 阿司匹林对系统性红斑狼疮妊娠者结局的影响[J]. 北京大学学报（医学版）, 2025, 57(6): 1074-1080.
[4]	王晓林, 郭邵逸, 陈大召, 温锡杰, 华勇, 张亮, 张秦. 全髋关节置换术治疗系统性红斑狼疮继发股骨头缺血性坏死的随访研究[J]. 北京大学学报（医学版）, 2025, 57(6): 1081-1088.
[5]	卫春, 杨月, 赵新菊, 刘栩, 贾园. 系统性红斑狼疮合并自身免疫性郎飞结病1例[J]. 北京大学学报（医学版）, 2025, 57(6): 1174-1179.
[6]	梁景原, 张霞, 姚海红. 误诊为系统性硬化症的POEMS综合征1例[J]. 北京大学学报（医学版）, 2025, 57(6): 1184-1187.
[7]	赵凯, 鲁芙爱, 王永福. 中枢神经系统感染模拟神经精神狼疮1例[J]. 北京大学学报（医学版）, 2025, 57(6): 1188-1192.
[8]	王小梦, 曾晓君, 李娟. 黎族与汉族系统性红斑狼疮患者的主要临床特征[J]. 北京大学学报（医学版）, 2025, 57(6): 1213-1218.
[9]	曹沛, 栾庆先. 牙周炎与全身系统性疾病的思考与探索[J]. 北京大学学报（医学版）, 2025, 57(5): 852-858.
[10]	袁显墩, 李照华, 徐丹, 李婷, 方丹, 穆荣. 丝氨酸蛋白酶23在系统性硬化病皮肤纤维化中的作用和机制[J]. 北京大学学报（医学版）, 2025, 57(5): 903-910.
[11]	王文琼, 侯玉珂, 李春, 张学武. 系统性红斑狼疮患者不良妊娠结局的预测因素[J]. 北京大学学报（医学版）, 2025, 57(3): 599-603.
[12]	王红彦, 李鑫铭, 房柯池, 朱华群, 贾汝琳, 王晶. 系统性红斑狼疮疾病活动度相关特征分析及评估模型的构建[J]. 北京大学学报（医学版）, 2024, 56(6): 1017-1022.
[13]	陈丹丹, 李云, 卢情怡, 相晓红, 孙峰, 李英妮, 赵静, 王红彦, 李春. 育龄期系统性红斑狼疮患者卵巢功能的评价及其影响因素[J]. 北京大学学报（医学版）, 2024, 56(6): 1023-1028.
[14]	王莉, 高超, 任欢欢, 沈艳平, 黄晓玮, 姚鸿, 韩丹丹. 系统性红斑狼疮患者自我管理能力现状及相关因素分析[J]. 北京大学学报（医学版）, 2024, 56(6): 1029-1035.
[15]	潘苇, 李云, 罗俊佳, 李春, 叶华, 李雪, 贾园. 系统性硬化症患者新型冠状病毒感染特点及疫苗接种效果：一项单中心队列研究[J]. 北京大学学报（医学版）, 2024, 56(6): 1041-1046.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed